Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. (ACHV) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
achv · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Achieve Life Sciences, Inc. (ACHV) measures how much investors pay for each dollar of the company's trailing earnings. ACHV's current PE ratio of N/A is calculated by dividing its stock price of $5.47 by its TTM earnings per share of -$0.97.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Achieve Life Sciences, Inc.You ACHV | $562M | N/A | — | -$0.97 |
 Allogene Therapeutics, Inc. ALLO | $451M | N/A | — | -$0.87 |
 Arcturus Therapeutics Holdings Inc. ARCT | $209M | N/A | — | -$2.40 |
 Atea Pharmaceuticals, Inc. AVIR | $353M | N/A | — | -$1.94 |
 Capricor Therapeutics, Inc. CAPR | $1.2B | N/A | — | -$2.26 |
 Humacyte, Inc. HUMA | $237M | N/A | — | -$0.26 |
 Immuneering Corporation IMRX | $153M | N/A | — | -$1.27 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.25 | — | |
2024-12-31 FY2024 | — | $-1.24 | — | |
2023-12-31 FY2023 | — | $-1.50 | — | |
2022-12-31 FY2022 | — | $-4.00 | — | |
2021-12-31 FY2021 | — | $-4.08 | — | |
2020-12-31 FY2020 | — | $-5.39 | — | |
2019-12-31 FY2019 | — | $-39.76 | — | |
2018-12-31 FY2018 | — | $-72.29 | — | |
2017-12-31 FY2017 | — | $-441.47 | — | |
2016-12-31 FY2016 | — | $-1478.66 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Achieve Life Sciences, Inc. (ACHV) measures how much investors pay for each dollar of the company's trailing earnings. ACHV's current PE ratio of N/A is calculated by dividing its stock price of $5.47 by its TTM earnings per share of -$0.97.
Frequently asked questions
ACHV pe ratio · 6 questionsACHV's current PE ratio is N/A as of 2026-06-08, based on a stock price of $5.47 and TTM EPS of -$0.97. Data sourced from Financial Modeling Prep via ACHV's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Achieve Life Sciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08